RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 ISAR-LEFT MAIN 2 Trial: Zotarolimus- versus Everolimus- Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 17
SP 21
OP 21
DO 10.1177/155989771217009
UL http://mdc.sagepub.com/content/12/17/21.abstract
AB The original Drug-eluting Stents for Unprotected Left Main Stem Disease [ISAR-Left Main] study found no significant difference in outcomes for patients with unprotected left main coronary artery stenosis (uLMCS) who were treated with first generation paclitaxel-eluting versus sirolimus-eluting stents [Mehilli J et al. J Am Coll Cardiol 2009]. The objective of the current ISAR-LEFT MAIN 2 trial [NCT00598637] was to compare the performance of zotarolimus-eluting stent versus everolimus-eluting stent in patients with uLMCS lesions, using a noninferiority design.